<DOC>
	<DOCNO>NCT01471067</DOCNO>
	<brief_summary>The goal clinical research study learn safe feasible transplant change cord blood patient leukemia lymphoma . Researchers also want learn help control disease . The cord blood change make use sugar find small amount blood cell . It play role signal body transplant cell go . Adding sugar cord blood cell laboratory design help cord blood cell find way faster bone marrow . This may help blood count recover faster . This process call fucosylation . Anti-thymocyte globulin ( ATG ) protein remove immune cell cause damage body . Clofarabine design interfere growth development cancer cell . Fludarabine design interfere DNA ( genetic material ) cancer cell , may cause cancer cell die . This chemotherapy also design block body 's ability reject donor 's bone marrow cell . Melphalan busulfan design bind DNA cell , may cause cancer cell die . Mycophenolate mofetil ( MMF ) tacrolimus design block donor cell grow spread way could cause graft versus host disease ( GVHD -- condition transplant tissue attack recipient 's body ) . This may help prevent GVHD . Rituximab design attach cancer cell , may cause die .</brief_summary>
	<brief_title>Cord Blood Fucosylation Enhance Homing Engraftment Patients With Hematologic Malignancies</brief_title>
	<detailed_description>Central Venous Catheter Placement : You first central venous catheter ( CVC ) place . A CVC sterile flexible tube place large vein local anesthesia . Your doctor explain procedure detail , require sign separate consent form . The chemotherapy , drug study , cord blood transplant give vein CVC . Blood sample also draw CVC . The CVC remain body 2-5 month . Study Plans : If agree take part study , doctor choose one follow 2 study plan base disease age medical history . Fludarabine/Clofarabine/Busulfan/Rituximab/Total Body Irradiation : If 1 55 year age receive high-dose chemotherapy , 55 65 year old doctor agree , receive fludarabine , clofarabine , busulfan , ATG , total body irradiation , possibly rituximab . You receive test dose busulfan vein 60 minute outpatient . If test dose give outpatient , admitted hospital Day -10 intravenous ( IV ) fluid receive busulfan test dose Day -9 . This low-level `` test '' dose busulfan check level busulfan blood change time . This information use decide next dose need reach target blood level match body size . About 11 sample blood draw pharmacokinetic ( PK ) test busulfan . PK test measure amount study drug body different time point . These blood sample draw various timepoints start busulfan infusion continue next 11 hour . The blood sample repeat first day high-dose busulfan treatment . Each sample 1 teaspoon blood . A temporary heparin lock place vein low number needle stick need draws . If possible PK test perform technical scheduling reason , receive standard fix dose busulfan . If receive test dose outpatient , admitted hospital Day -8 receive fluid vein . If appropriate disease , receive rituximab vein 4-6 hour Day -8 . If receive test dose inpatient , admit Day -10 receive fluid vein . If appropriate disease , receive rituximab vein 4-6 hour Day -10 . On Days -7 -4 , receive fludarabine vein 1 hour , clofarabine vein 1 hour , busulfan vein 3 hour . You receive ATG Days -4 -3 . On Day -3 , receive single treatment low-dose total body irradiation . You `` rest '' ( receive chemotherapy drug ) Days -2 -1 . Day 0 day cord blood transplant , negative day number use label treatment day transplant . All chemotherapy drug , fluid , drug must give vein infuse catheter . Once back-up cell collect , participant admit hospital indicate assign treatment plan schedule . Fludarabine/Melphalan : If doctor choose fludarabine melphalan , follow schedule : - On Day -6 ( 6 day transplant ) , admit hospital receive fluid vein . - On Days -5 , -4 , -3 , receive fludarabine vein 30 minute . - On Days -4 -3 , receive ATG vein 4 hour . - On Day -2 , receive fludarabine vein 30 minute melphalan vein 30 minute . - On Day -1 , receive drug . - On Day 0 , receive cord blood transplant CVC . Supportive Drugs : Starting Day -3 , receive mycophenolate mofetil tablet mouth 2 time day . If able take tablet mouth , receive MMF vein 2 hour 2 time day . If GVHD Day 100 cord blood transplant , dose MMF gradually lower . If GVHD , MMF may stop 7 day GVHD control . Starting Day -2 , receive tacrolimus vein continuous ( nonstop ) infusion able take mouth . You take tacrolimus mouth 2 time day 6 month . After , tacrolimus dose may gradually lower GVHD . Your doctor discus . Starting Day 0 , receive filgrastim ( G-CSF ) needle skin 1 time day every day white blood count begin recover . Filgrastim design help cell bone marrow divide , help raise white blood cell count quickly , low fever , decrease risk infection . Study Visits : At 1 , 3 , 6 , 12 month transplant : - You physical exam . - You check possible reaction transplant study drug , include GVHD . - Blood ( 4 teaspoon ) draw routine test , check CMV antibody , genetic test learn donor 's cell `` take '' . The routine blood test repeat often doctor think need . - If doctor think need , bone marrow aspiration check status disease . You need stay hospital 4 week . After leave hospital , continue outpatient hospital area , mean stay close enough able come back visit 100 day transplant . Length Participation : You study 1 year . You take study early disease get bad , intolerable side effect occur , cord blood infect transplant , unable follow study direction , doctor think best interest . This investigational study . Fucosylation FDA-approved process . It currently use research purpose . Fludarabine , busulfan , clofarabine , melphalan , mycophenolate mofetil , tacrolimus , rituximab FDA approve commercially available give patient leukemia lymphoma cord blood transplant . Total body irradiation deliver use FDA-approved commercially available method . Up 50 patient enrol study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Clofarabine</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>1 . Patients must one follow hematologic malignancy : Acute Myelogenous Leukemia ( AML ) , induction failure , highrisk relapse first remission ( intermediaterisk highrisk cytogenetics , flt3 mutation positive and/or evidence minimal residual disease flow cytometry ) , secondary leukemia prior chemotherapy and/or arise MDS , Langerhan 's cell histiocytosis , disease beyond first remission ; , 2 . Myelodysplastic Syndrome ( MDS ) : Primary therapy relate ; , 3 . Acute Lymphoblastic Leukemia ( ALL ) : induction failure , primary refractory treatment ( achieve complete remission first course therapy ) beyond first remission include second great remission active disease . Patients first remission eligible consider high risk , define follow detected time : translocation 9 ; 22 4 ; 11 , hypodiploidy , complex karyotype , secondary leukemia develop cytotoxic drug exposure , and/or evidence minimal residual disease , acute biphenotypic leukemia , double hit nonHodgkin 's lymphoma ; , 4 . NonHodgkin 's Lymphoma ( NHL ) primary induction failure , second third complete remission , refractory disease , relapse ( include relapse post autologous hematopoietic stem cell transplant ) . Double hit lymphoma first remission advance disease ; , 5 . Small Lymphocytic Lymphoma ( SLL ) , Chronic Lymphocytic Leukemia ( CLL ) progressive disease follow standard therapy ; , 6 . CML second chronic phase accelerate phase ; , 7 . Hodgkin 's Disease ( HD ) : Induction failure , second third complete remission , relapse ( include relapse post autologous hematopoietic stem cell transplant ) . 8 . Patients Age Criteria : Age &gt; /= 1 &lt; /= 80 year old . Eligibility pediatric patient determine conjunction MDACC pediatrician . 9 . Performance score least 80 % Karnofsky PS &lt; 3 ( ECOG ) ( age &gt; /= 12 year ) , Lansky PlayPerformance Scale least 60 % great ( age &lt; 12 year ) . 10 . Adequate major organ system function demonstrate : . Left ventricular ejection fraction least 4045 % b . Pulmonary function test ( PFT ) demonstrate diffusion capacity least 50 % predict . For child &lt; /= 7 year age unable perform PFT , oxygen saturation &gt; /= 92 % room air pulse oximetry . c. Creatinine &lt; 1.6 mg/dL . d. SGPT/bilirubin &lt; /= 2.0 x normal . 11 . Negative Beta HCG test woman child bear potential define postmenopausal 12 month previous surgical sterilization willing use effective contraceptive measure study . 12 . Patients must two CB unit available match patient 4 , 5 , 6/6 HLA class I ( serological ) II ( molecular ) antigen . Each cord must contain least 1.5 x 10^7 total nucleated cells/Kg recipient body weight ( prethaw ) . 13 . Have identify backup cell source case engraftment failure . The source autologous , related unrelated . 1 . Patients known history HIV/AIDS . 2 . Active CNS disease patient history CNS malignancy . 3 . Patients chronic active hepatitis cirrhosis . If positive hepatitis serology , Study Chair may deem patient eligible base result liver biopsy . 4 . Patients uncontrolled serious medical condition persistent septicemia despite adequate antibiotic therapy , decompensated congestive heart failure despite cardiac medication pulmonary insufficiency require intubation ( exclude primary disease CB transplantation propose ) , psychiatric condition would limit informed consent . 5 . Positive beta HCG female childbearing potential define postmenopausal 12 month previous surgical sterilization breastfeeding .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Blood And Marrow Transplantation</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Pediatrics</keyword>
	<keyword>Cord blood transplant</keyword>
	<keyword>Cord Blood Fucosylation</keyword>
	<keyword>Hematologic Malignancies</keyword>
	<keyword>Acute Myelogenous Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>MDS</keyword>
	<keyword>High-risk cytogenetics</keyword>
	<keyword>Secondary leukemia prior chemotherapy</keyword>
	<keyword>Langerhan 's cell histiocytosis</keyword>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
	<keyword>ALL</keyword>
	<keyword>complete remission</keyword>
	<keyword>Philadelphia chromosome</keyword>
	<keyword>translocation 4 ; 11</keyword>
	<keyword>Hypodiploidy</keyword>
	<keyword>Chronic Myeloid Leukemia</keyword>
	<keyword>CML</keyword>
	<keyword>Non-Hodgkin 's Lymphoma</keyword>
	<keyword>NHL</keyword>
	<keyword>Hodgkin 's Disease</keyword>
	<keyword>HD</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>CLL</keyword>
	<keyword>Melphalan</keyword>
	<keyword>Alkeran</keyword>
	<keyword>Thiotepa</keyword>
	<keyword>Fludarabine</keyword>
	<keyword>Fludarabine Phosphate</keyword>
	<keyword>Fludara</keyword>
	<keyword>Mycophenolate Mofetil</keyword>
	<keyword>MMF</keyword>
	<keyword>CellCept</keyword>
	<keyword>Tacrolimus</keyword>
	<keyword>Prograf</keyword>
	<keyword>Rituximab</keyword>
	<keyword>Rituxan</keyword>
	<keyword>ATG</keyword>
	<keyword>Antithymocyte Globulin</keyword>
	<keyword>Thymoglobulin</keyword>
</DOC>